Is there a generic version of lorlatinib/lorlatinib?

Lorlatinib/Lorratinib (Lorlatinib), as a third-generation ALK inhibitor, has shown good therapeutic effect in the treatment of ALK-positive non-small cell lung cancer (NSCLC), especially for patients who are resistant to previous first- or second-generation ALK inhibitors.

The original drug is developed and sold by Pfizer. However, due to the high price of the original drug and some patients' financial pressure, several generic versions have appeared on the market. These generic drugs are mainly produced in some Asian and developing countries, such as Lucius Pharmaceuticals in Laos, Daxiong Pharmaceuticals, United Pharmaceuticals, and Everest Pharmaceuticals in Bangladesh. The ingredients of these drugs are highly consistent with the original drugs, and their efficacy and safety are similar in principle.

Take the 100mg*30 tablets produced by Lucius Pharmaceuticals in Laos as an example. Its price is about 1,000 yuan, but due to differences in exchange rates and regional policies, the actual selling price may fluctuate. Although generic drugs can reduce the financial burden on patients, when choosing to use them, special attention should be paid to the source channels and authenticity of the drugs, ensuring that products from regular manufacturers are purchased and used under the guidance of a doctor to avoid medication risks or unstable efficacy.

In addition, for patients who are being treated with lorlatinib, do not change drug brands or dosages at will to avoid affecting disease control. When economic conditions permit, priority should be given to using original drugs to obtain safety and efficacy that have been rigorously clinically verified; for patients who must use generic drugs, the source of the drugs should be ensured to be reliable, and treatment monitoring should be carried out regularly, and hematological indicators and liver function should be paid attention to in order to adjust the treatment plan in a timely manner.

Overall, the emergence of generic lorlatinib drugs has provided patients with more choices, but drug safety, quality assurance and clinical monitoring are still priorities that cannot be ignored.

Keyword tags: Lolatinib generic drugs,Lorlatinib price, ALK-positive lung cancer treatment, economical anti-cancer drugs, Laos Lucius Pharmaceuticals, Bangladesh Everest Pharmaceuticals

References:https://www.medicines.org.uk/emc/product/10701/smpc